The Utility of Spectroscopic MRI in Stereotactic Biopsy and Radiotherapy Guidance in Newly Diagnosed Glioblastoma
Authors:
- Abinand C. RejimonARAbinand C. Rejimon
- Karthik K. RameshKRKarthik K. Ramesh
- Anuradha G. TrivediATAnuradha G. Trivedi
- Vicki HuangVHVicki Huang
- Eduard SchreibmannESEduard Schreibmann
- Brent D. WeinbergBrent D. Weinberg
- Lawrence R. KleinbergLKLawrence R. Kleinberg
- Hui-Kuo G. ShuHui-Kuo G. Shu
- Hyunsuk ShimHSHyunsuk Shim
- Jeffrey J. OlsonJOJeffrey J. Olson
Open Access
- 20 March 2024
- journal article
- research article
- Published by MDPI AG in Tomography
- Vol. 10 (3) , 428-443
Abstract
Current diagnostic and therapeutic approaches for gliomas have limitations hindering survival outcomes. We propose spectroscopic magnetic resonance imaging as an adjunct to standard MRI to bridge these gaps. Spectroscopic MRI is a volumetric MRI technique capable of identifying tumor infiltration based on its elevated choline (Cho) and decreased N-acetylaspartate (NAA). We present the clinical translatability of spectroscopic imaging with a Cho/NAA ≥ 5x threshold for delineating a biopsy target in a patient diagnosed with non-enhancing glioma. Then, we describe the relationship between the undertreated tumor detected with metabolite imaging and overall survival (OS) from a pilot study of newly diagnosed GBM patients treated with belinostat and chemoradiation. Each cohort (control and belinostat) were split into subgroups using the median difference between pre-radiotherapy Cho/NAA ≥ 2x and the treated T1-weighted contrast-enhanced (T1w-CE) volume. We used the Kaplan–Meier estimator to calculate median OS for each subgroup. The median OS was 14.4 months when the difference between Cho/NAA ≥ 2x and T1w-CE volumes was higher than the median compared with 34.3 months when this difference was lower than the median. The T1w-CE volumes were similar in both subgroups. We find that patients who had lower volumes of undertreated tumors detected via spectroscopy had better survival outcomes.Keywords
Funding Information
- National Institutes of Health (U01 CA264039, F31 CA247564)
This publication has 43 references indexed in Scilit:
- SimpleITK Image-Analysis Notebooks: a Collaborative Environment for Education and Reproducible ResearchJournal of Digital Imaging, 2017
- Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for GlioblastomaJAMA, 2015
- Multivendor implementation and comparison of volumetric whole‐brain echo‐planar MR spectroscopic imagingMagnetic Resonance in Medicine, 2014
- Mapping of brain metabolite distributions by volumetric proton MR spectroscopic imaging (MRSI)Magnetic Resonance in Medicine, 2008
- Comprehensive processing, display and analysis for in vivo MR spectroscopic imagingNMR in Biomedicine, 2006
- Multiparametric 3T MR approach to the assessment of cerebral gliomas: tumor extent and malignancyNeuroradiology, 2006
- Serial evaluation of patients with brain tumors using volume MRI and 3D1H MRSINMR in Biomedicine, 1999
- Role of stereotactic biopsy in the diagnosis and management of brain tumorsSeminars in Surgical Oncology, 1998
- Localised proton spectroscopy and spectroscopic imaging in cerebral gliomas, with comparison to positron emission tomographyNeuroradiology, 1995
- A review of chemical issues in 1H NMR spectroscopy: N‐acetyl‐l‐aspartate, creatine and cholineNMR in Biomedicine, 1991